Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

Published:1999-01 Issue:1 Volume:72 Page:60-64
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Bolis Giorgio,Parazzini Fabio,Scarfone Giovanna,Villa Antonella,Amoroso Mariangela,Rabaiotti Emanuela,Polatti Anna,Reina Simona,Pirletti Elena

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference18 articles.

1. Cancer of the ovary;Cannistra;N Engl J Med,1993

2. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer;Bolis;J Clin Oncol,1997

3. Second-line chemotherapy for recurrent carcinoma of the ovary;Thigpen;Cancer,1993

4. Clinical trials in patients with epithelial ovarian cancer: past, present and future;Vermorken;Eur J Surg Oncol,1996

5. High-dose intensity regimens with epirubicin in ovarian cancer;Vermorken;Semin Oncol,1994

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression;Biochemical and Biophysical Research Communications;2022-10

2. Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial;Journal of Gynecologic Oncology;2021

3. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG;Journal of Gynecologic Oncology;2020

4. Metronomic Chemotherapy in Gynecological Cancers;Metronomic Chemotherapy;2014

5. Update on randomized trials on recurrent disease;Annals of Oncology;2013-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3